Spots Global Cancer Trial Database for carcinoma, squamous cell
Every month we try and update this database with for carcinoma, squamous cell cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0) | NCT00563862 | Nasopharyngeal ... Carcinoma, Squa... | Conventional RT Accelerated RT Cisplatin 5-fluorouracil | - 70 Years | Hospital Authority, Hong Kong | |
| Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | NCT03336606 | Head and Neck C... Head and Neck S... Melanoma Cell Cancer, Sq... Carcinoma, Squa... | MEDI0562 | 18 Years - | Providence Health & Services | |
| Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer | NCT03067610 | Head and Neck C... Carcinoma, Squa... Neoplasms, Oral Neoplasms, Phar... | Intensity Modul... chemotherapy | 18 Years - 99 Years | University of Texas Southwestern Medical Center | |
| Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa | NCT06094829 | Carcinoma, Squa... | Oral cytobrush | 18 Years - | Hospices Civils de Lyon | |
| Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone | NCT00041626 | Carcinoma, Squa... | INGN 201 | 18 Years - | Introgen Therapeutics | |
| GDF15 Based TPF Induction Chemotherapy for OSCC Patients | NCT02285530 | Mouth Neoplasms Carcinoma, Squa... | TPF induction c... surgery group Post-operative ... | 18 Years - 75 Years | Shanghai Jiao Tong University School of Medicine | |
| Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma | NCT02549638 | Carcinoma, Squa... Carcinoma, Squa... Squamous Cell C... Lung Neoplasms Cancer of Lung Cancer of the L... Lung Cancer Neoplasms, Lung Neoplasms, Pulm... Pulmonary Cance... Pulmonary Neopl... | DNA Extraction | 18 Years - | Mayo Clinic | |
| Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers | NCT02994069 | Carcinoma, Squa... Head and Neck C... | Cisplatin XRT | 18 Years - | University of Kentucky | |
| STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE | NCT02328391 | Carcinoma, Squa... | 18 Years - | Grupo Gallego de Cancer de Pulmon | ||
| Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients | NCT02526953 | Anus Neoplasms Carcinoma, Squa... Anus Diseases Neoplasms Neoplasms, Squa... Carcinoma | Paclitaxel Capecitabine Capecitabine Mitomycins Mitomycins Radiotherapy | 18 Years - 70 Years | Blokhin's Russian Cancer Research Center | |
| Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck | NCT00233636 | Head and Neck C... Carcinoma, Squa... | Iressa (Gefitin... Radiotherapy | 18 Years - | AstraZeneca | |
| Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer | NCT00448240 | Head and Neck C... Carcinoma, Squa... | Erlotinib | 18 Years - | Henry Ford Health System | |
| De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca | NCT01530997 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin Limited surgica... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| BIBW 2992 (Afatinib) in Head & Neck Cancer | NCT00514943 | Head and Neck N... Carcinoma, Squa... | BIBW 2992 Cetuximab | 18 Years - | Boehringer Ingelheim | |
| Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial | NCT03769285 | Non-melanoma Sk... Carcinoma, Squa... Carcinoma, Basa... | Nicotinamide Placebo oral ca... | 18 Years - | Women's College Hospital | |
| Neck Dissection Via a Robot-assisted Transaxillary Approach in Patients With Squamous Cell Carcinoma of the Epi-larynx | NCT02269020 | Carcinoma, Squa... | Neck Dissection | 18 Years - 89 Years | Centre Hospitalier Universitaire de Nīmes | |
| Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0) | NCT00563927 | Nasopharyngeal ... Carcinoma, Squa... | Conventional RT Cisplatin 5-fluorouracil | - 70 Years | Hospital Authority, Hong Kong | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| Patient Evaluation for Head and Neck Surgery Branch Studies | NCT00011492 | Head and Neck N... Pharyngeal Canc... Oral Cancer Carcinoma, Squa... Laryngeal Cance... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck | NCT00474825 | Carcinoma, Squa... Cancer of the H... | Hyperbaric Oxyg... Hyperbaric Oxyg... Hyperbaric oxyg... Hyperbaric oxyg... | 18 Years - 70 Years | National Baromedical Services | |
| Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | NCT03336606 | Head and Neck C... Head and Neck S... Melanoma Cell Cancer, Sq... Carcinoma, Squa... | MEDI0562 | 18 Years - | Providence Health & Services | |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | NCT04429542 | Head and Neck S... Squamous Cell C... Colorectal Canc... Squamous Cell C... EGFR Amplificat... Epithelial Ovar... Pancreas Cancer Cutaneous Squam... Head and Neck N... Carcinoma, Squa... Squamous Cell C... | BCA101 Pembrolizumab | 18 Years - | Bicara Therapeutics | |
| Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck | NCT01491139 | Carcinoma, Squa... | olaparib cisplatin Intensity Modul... | 18 Years - | University College, London | |
| Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer | NCT04050436 | Cutaneous Squam... Advanced Cutane... Metastatic Cuta... | Cemiplimab RP1 | 18 Years - | Replimune Inc. | |
| Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma | NCT02549638 | Carcinoma, Squa... Carcinoma, Squa... Squamous Cell C... Lung Neoplasms Cancer of Lung Cancer of the L... Lung Cancer Neoplasms, Lung Neoplasms, Pulm... Pulmonary Cance... Pulmonary Neopl... | DNA Extraction | 18 Years - | Mayo Clinic | |
| Detecting Lesions in the Oral Cavity With Thermal Imaging | NCT00868725 | Carcinoma, Squa... | no intervention... | - | Sheba Medical Center | |
| Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC | NCT00130780 | Carcinoma, Non-... | Pre-surgical Tr... Pre-Surgical Do... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Uniform FDG-PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity | NCT02442375 | Head and Neck N... Carcinoma, Squa... | standard dose p... FDG-PET guided ... | 18 Years - 80 Years | Radboud University Medical Center | |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | NCT05970497 | Cancer Melanoma Stage ... Melanoma Stage ... Cutaneous Melan... Osteosarcoma Carcinoma, Squa... Carcinoma, Basa... | KB707 | 18 Years - | Krystal Biotech, Inc. | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | NCT05552807 | Head and Neck S... | SCT-I10A SCT200 paclitaxel docetaxel | 18 Years - | Sinocelltech Ltd. | |
| Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer | NCT00272181 | Squamous Cell C... Carcinoma, Squa... Neoplasms, Squa... Head and Neck N... Mouth Neoplasms Head and Neck C... | Proxinium | 18 Years - | Sesen Bio, Inc. | |
| Phase II AK Study in Organ Transplant Patients | NCT00829192 | Actinic Keratos... Carcinoma, Squa... Organ Transplan... | Afamelanotide (... Placebo | 18 Years - 75 Years | Clinuvel Pharmaceuticals Limited | |
| Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer | NCT02027428 | Squamous Cell C... | Abraxane (Induc... Carboplatin (In... Abraxane (Maint... Best Supportive... Abraxane (Induc... Carboplatin (In... Best Supportive... | 18 Years - | Celgene | |
| Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | NCT03174275 | Carcinoma, Squa... Oral Cancer Oropharynx Canc... Larynx Cancer Lip Cancer Esophageal Canc... | Durvalumab Carboplatin Nab-paclitaxel Cisplatin Surgical resect... IMRT | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer | NCT05388773 | Oropharynx Canc... | therapeutic con... laboratory biom... quality-of-life... intensity-modul... Cisplatin Carboplatin | 18 Years - | University of Pittsburgh | |
| Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer | NCT02107235 | Head and Neck N... Carcinoma, Squa... | oral rigosertib cisplatin Radiotherapy | 18 Years - | Traws Pharma, Inc. | |
| P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC | NCT03077243 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin (or a... Assessment for ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia | NCT01362127 | Carcinoma, Squa... Adenocarcinoma ... | Chemotherapy Radiochemothera... | 18 Years - 75 Years | Karolinska University Hospital | |
| The Clinical Study of the Poorly Differentiated Head and Neck Squamous Cell Carcinoma | NCT02916368 | Carcinoma, Squa... | 18 Years - 70 Years | Beijing Tongren Hospital | ||
| TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN | NCT00539630 | Carcinoma, Squa... | Docetaxel | 18 Years - 70 Years | Sanofi | |
| Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer | NCT00368329 | Esophageal Neop... Carcinoma, Squa... Adenocarcinoma Esophageal Canc... | Capecitabine (X... [18-F] Fluorode... 5-Fluorouracil ... Carboplatin | 18 Years - | Stanford University | |
| Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer | NCT00448240 | Head and Neck C... Carcinoma, Squa... | Erlotinib | 18 Years - | Henry Ford Health System | |
| A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck | NCT01075841 | Neoplasms, Squa... | Cetuximab | - | Merck KGaA, Darmstadt, Germany | |
| Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck | NCT00474825 | Carcinoma, Squa... Cancer of the H... | Hyperbaric Oxyg... Hyperbaric Oxyg... Hyperbaric oxyg... Hyperbaric oxyg... | 18 Years - 70 Years | National Baromedical Services | |
| Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma | NCT02218164 | Squamous Cell C... Carcinoma, Squa... | Pegylated Inter... Capecitabine 5-FU | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) | NCT00632203 | Carcinoma, Non-... Adenocarcinoma Carcinoma, Larg... Carcinoma, Squa... | Temozolomide | 18 Years - | Merck Sharp & Dohme LLC | |
| INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT05359692 | Metastatic Head... Advanced Malign... Recurrent Head ... | INCAGN01876 retifanlimab | 18 Years - 99 Years | Incyte Corporation | |
| Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck | NCT00233636 | Head and Neck C... Carcinoma, Squa... | Iressa (Gefitin... Radiotherapy | 18 Years - | AstraZeneca | |
| Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ | NCT00329121 | Carcinoma, Squa... | PEP005 | 18 Years - | Peplin | |
| Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer | NCT00368329 | Esophageal Neop... Carcinoma, Squa... Adenocarcinoma Esophageal Canc... | Capecitabine (X... [18-F] Fluorode... 5-Fluorouracil ... Carboplatin | 18 Years - | Stanford University | |
| Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer | NCT02107235 | Head and Neck N... Carcinoma, Squa... | oral rigosertib cisplatin Radiotherapy | 18 Years - | Traws Pharma, Inc. | |
| TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY | NCT04481256 | Carcinoma, Squa... Oesophageal Can... | External beam r... Bintrafusp alfa Paclitaxel Carboplatin | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa | NCT06094829 | Carcinoma, Squa... | Oral cytobrush | 18 Years - | Hospices Civils de Lyon | |
| Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer | NCT03051906 | Head and Neck N... | Durvalumab Cetuximab Intensity modul... | 18 Years - | Azienda Ospedaliero-Universitaria Careggi | |
| Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis | NCT02844777 | Actinic Keratos... | Placebo 5% VDA-1102 10% VDA-1102 | 18 Years - | Vidac Pharma | |
| Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage | NCT02290145 | Mouth Neoplasms Carcinoma, Squa... | TPF group surgery group Post-operative ... | 18 Years - 75 Years | Shanghai Jiao Tong University School of Medicine | |
| Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck | NCT00185835 | Head and Neck C... Carcinoma, Squa... | ZD-1839 Cisplatin | 18 Years - | Stanford University | |
| Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract | NCT01175499 | Upper Aerodiges... Neoplasms, Orop... Oropharyngeal C... Neoplasms, Hypo... Hypopharyngeal ... Head and Neck N... UADT Neoplasms Carcinoma, Squa... Papilloma | Direct Rigid En... Transnasal Flex... | 18 Years - | University of California, San Francisco | |
| Detecting Lesions in the Oral Cavity With Thermal Imaging | NCT00868725 | Carcinoma, Squa... | no intervention... | - | Sheba Medical Center | |
| P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC | NCT03077243 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin (or a... Assessment for ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | NCT01142869 | Carcinoma, Squa... | Cetuximab | - | Merck KGaA, Darmstadt, Germany | |
| Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate | NCT00041613 | Carcinoma, Squa... | INGN 201 | 18 Years - | Introgen Therapeutics | |
| Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients | NCT05252078 | Esophageal Squa... Esophageal Neop... Esophageal Dise... Gastrointestina... Gastrointestina... Digestive Syste... Digestive Syste... Neoplasms by Si... Neoplasms by Hi... Neoplasms, Squa... Carcinoma, Squa... | Anlotinib hydro... TQB2450 | 18 Years - | Jiangxi Provincial Cancer Hospital | |
| Safety Study of SEA-CD40 in Cancer Patients | NCT02376699 | Carcinoma, Non-... Carcinoma, Squa... Hodgkin Disease Lymphoma Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Large... Melanoma Neoplasm Metast... Neoplasms, Head... Neoplasms, Squa... Non-Small Cell ... Non-Small Cell ... Non-small Cell ... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell N... Lymphoma, Non-H... Pancreatic Aden... | Intravenous (IV... Pembrolizumab Subcutaneous (S... Gemcitabine Nab-paclitaxel | 18 Years - | Seagen Inc. | |
| Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor Risk | NCT00937612 | Head and Neck N... Carcinoma, Squa... | Radiotherapy | 18 Years - 70 Years | Chang Gung Memorial Hospital | |
| Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) | NCT00632203 | Carcinoma, Non-... Adenocarcinoma Carcinoma, Larg... Carcinoma, Squa... | Temozolomide | 18 Years - | Merck Sharp & Dohme LLC | |
| Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | NCT04564989 | Oropharyngeal S... Carcinoma, Squa... Head and Neck S... Oropharynx Squa... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma | NCT02218164 | Squamous Cell C... Carcinoma, Squa... | Pegylated Inter... Capecitabine 5-FU | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma | NCT01195922 | Mouth Neoplasms Head and Neck N... Tongue Neoplasm... Carcinoma, Squa... | Sirolimus | 18 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Safety Study of SEA-CD40 in Cancer Patients | NCT02376699 | Carcinoma, Non-... Carcinoma, Squa... Hodgkin Disease Lymphoma Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Large... Melanoma Neoplasm Metast... Neoplasms, Head... Neoplasms, Squa... Non-Small Cell ... Non-Small Cell ... Non-small Cell ... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell N... Lymphoma, Non-H... Pancreatic Aden... | Intravenous (IV... Pembrolizumab Subcutaneous (S... Gemcitabine Nab-paclitaxel | 18 Years - | Seagen Inc. | |
| Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer | NCT01494415 | Carcinoma, Non-... Carcinoma, Squa... | Paclitaxel for ... carboplatin thoracic radiat... | 18 Years - 75 Years | First People's Hospital of Hangzhou | |
| Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus | NCT02254044 | Carcinoma, Squa... | bivatuzumab mer... | 18 Years - 80 Years | Boehringer Ingelheim | |
| Spanish Registry of Mohs Surgery | NCT02310503 | Skin Neoplasms Carcinoma, Basa... Carcinoma, Squa... Dermatofibrosar... Melanoma Histiocytoma, M... Neoplasms, Adne... | Mohs surgery | 18 Years - | Fundación Academia Española de Dermatología | |
| LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy | NCT01345682 | Head and Neck N... Carcinoma, Squa... | Afatinib Methotrexate | 18 Years - | Boehringer Ingelheim | |
| Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck | NCT00534950 | Carcinoma, Squa... | 5 vs 6 weekly f... | - | King Faisal Specialist Hospital & Research Center | |
| A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) | NCT06295809 | Carcinoma, Squa... Skin Neoplasms | Pembrolizumab V940 Surgery | 18 Years - | Merck Sharp & Dohme LLC | |
| Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma | NCT03817567 | Esophageal Squa... | recombinant ant... | 18 Years - 75 Years | Sinocelltech Ltd. | |
| A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck | NCT00358930 | Head and Neck N... Carcinoma, Squa... | ARQ 501 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Simultaneous Integrated Boost (SIB)- IMRT | NCT00389727 | Carcinoma, Squa... | Radiotherapy | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
